HC Wainwright Estimates Rezolute’s Q1 Earnings (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Rezolute in a research report issued to clients and investors on Thursday, September 18th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.27) for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($0.64) EPS and FY2029 earnings at ($0.46) EPS.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03).

Several other equities research analysts also recently weighed in on RZLT. Maxim Group increased their target price on shares of Rezolute from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday. BTIG Research reiterated a “buy” rating and set a $17.00 target price on shares of Rezolute in a research note on Thursday. Finally, Wedbush reiterated an “outperform” rating and set a $12.00 target price on shares of Rezolute in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and an average target price of $14.40.

Rezolute Stock Performance

Shares of RZLT opened at $7.70 on Monday. Rezolute has a fifty-two week low of $2.21 and a fifty-two week high of $8.81. The company has a market capitalization of $699.24 million, a price-to-earnings ratio of -7.94 and a beta of 0.02. The firm has a 50-day simple moving average of $6.62 and a 200-day simple moving average of $4.74.

Institutional Investors Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently modified their holdings of RZLT. BNP Paribas Financial Markets acquired a new position in shares of Rezolute during the 2nd quarter worth approximately $25,000. Ameritas Investment Partners Inc. acquired a new position in shares of Rezolute during the 2nd quarter worth approximately $30,000. Legal & General Group Plc acquired a new position in shares of Rezolute during the 2nd quarter worth approximately $32,000. Raymond James Financial Inc. acquired a new position in shares of Rezolute during the 2nd quarter worth approximately $46,000. Finally, Jeppson Wealth Management LLC acquired a new position in shares of Rezolute during the 1st quarter worth approximately $35,000. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.